

Name der Studie		Indikation	EudraCT Numer:	Phase	Studienleiter Center DD
<b>ATMOS</b>	BAY 1237592				
A non-randomized Two part Multi-center, Open-label, Single dose trial with an escalation part in untreated PAH and CTEPH patients (PART1), followed by a parallel group part untreated and pre-treated patients with PAH and CTEPH (PartB) to investigate the safety, tolerability and pharmacodynamics of inhaled BAY 1237592		PAH Pulmonary arterial Hypertension	2018-001791-37	1b	PD Dr. med. Michael Halank
		CTEPH Chronic Thromboembolic Pulmonary Hypertension			
<b>PULSAR</b>	A011-09				
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo when added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)		PAH Pulmonary arterial Hypertension	2017-004738-27	2	PD Dr. med. Michael Halank
<b>SERENADE</b>	AC-055G202				
A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vasculature disease		heart failure	2016-003653-15	2b	PD Dr. med. Michael Halank
<b>REPLACE</b>	BAY 63-2521				
A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosphodiesterase-5 inhibitors (PDE-5i) with or without endothelin receptor antagonist (ERA), but not treatment goal		PAH Pulmonary arterial Hypertension	2016-001067-36	4	PD Dr. med. Michael Halank

<b>AFILIATE</b>									
A multinational, multicenter study to asses the effects of oral Sildenafil on mortality in adults with pulmonary arterial hypertension (PAH)					PAH Pulmonary arterial Hypertension	2013-004362-34	3b/4	PD Dr. med. Michael Halank	
<b>PASSION</b>									
Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension					heart failure	2017-003688-37	3	PD Dr. med. Michael Halank	
<b>SELECT</b>	AC-065B302								
A multicenter, randomizes, double-blind, placebo controlled, parallel-group, group-sequential, adaptive, Phase 3 study with open label extension period to assess the efficacy and safety of selexipag as an add-on to standard of care therapy in subjects with inoperable or persistent/recurrent after surgical tratment Chronic Thromboembolic Pulmonary Hypertension					Chronic Thromboembolic Pulmonary Hypertension	2018-002823-41	3	PD Dr. med. Michael Halank	
<b>TIVOLI</b>									
Use, safety and tolerability of IntraVenous epOprosteno (Veletri) in patients with severe pulmonary hypertension					PAH Pulmonary arterial Hypertension	not applicable	observational study	PD Dr. med. Michael Halank	

<b>CP40617</b>								
A Phase III, randomized, doubl-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Baloxavir Marboxil in combination with standard of care Neuraminidase Inhibitor in hospitalized patients with severe influenza	Infuenza	2018-001416-30	3	PD Dr. med. Martin Kolditz				
<b>CAPNETZ</b>	Community Acquired Pneumonia NETZwerk			prospektive Beobachtungsstudie				
Untersuchung der Prävalenz, Inzidenz und Risiken der ambulant erworbenen Pneumonie und ihre Interaktion mit Begleiterkrankungen in einer repräsentativen Stichprobe ambulanter und stationärer Patienten	Pneumonie	not applicable		PD Dr. med. Martin Kolditz				
<b>BAY 63-2521 12166</b>								
A multi-center, non-randomized, non-blinded, non-controlled, study to investigate the impact of multiple doses of BAY63-2521 on safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with interstitial lung disease associated pulmonary hypertension	PAH	not applicable	2	PD Dr. med. Michael Halank				
<b>Compera XL</b>								
A prospective structured data collection is often more suitable than a randomised study for addressing selected questions in everyday therapy. Therefore registers, surveys and epidemiological studies have gained great importance also in cardiology, as numerous examples show. <sup>24, 25</sup> They are particularly suitable for quality assurance, as individual centres can compare their results with other centres and with what is stated in guidelines.	pulmonary hypertension	not applicable	prospektive Beobachtungsstudie	PD Dr. med. Michael Halank				

<b>TDE-PH-311</b>							
An Open-Label Extension Study of UT-15C in Subjects with Pulmonary Arterial Hypertension-A Long-Term Follow-Up to Protocol TDE-PH--310	PAH	2012-000098-21	2	PD Dr. med. Michael Halank			
<b>TRITON</b>							
Die Wirksamkeit und Sicherheit einer anfänglich dreifach verglichen mit einer anfänglich zweifach oralen Kombinationstherapie bei Pateinten mit neu diagnostizierter pulmonal-arterielle Hypertonie	PAH	2015-003438-28	3b	PD Dr. med. Michael Halank			